328TiP Phase III study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first-line (1L), human epidermal growth factor receptor 2–positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09

Publication | Closed Access

DOI

Citations

References

2021

Year

Sara M. Tolaney, Romualdo Barroso‐Sousa, Z. Jiang, Y.H. Park, Mothaffar F. Rimawi, C. Saura Manich, Masakazu Toi, Tinghui Yu, Jagdish Shetty, Pia Herbolsheimer,

Annals of Oncology

Metastatic Breast CancerBreast OncologyMedicineTumor ImmunityCancer Cell BiologyPertuzumab VsBreast CancerMolecular OncologyDermatologyPhase Iii StudyCancer TreatmentOncologyRadiation OncologyCancer ResearchCancer Growth